FORA vs. ARYD, PLX, SPRO, IMAC, SRTS, ATHA, ACRS, GRTS, JATT, and ONCY
Should you be buying Forian stock or one of its competitors? The main competitors of Forian include ARYA Sciences Acquisition Corp IV (ARYD), Protalix BioTherapeutics (PLX), Spero Therapeutics (SPRO), IMAC (IMAC), Sensus Healthcare (SRTS), Athira Pharma (ATHA), Aclaris Therapeutics (ACRS), Gritstone bio (GRTS), JATT Acquisition (JATT), and Oncolytics Biotech (ONCY). These companies are all part of the "medical" sector.
ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD) and Forian (NASDAQ:FORA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, community ranking, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Forian has higher revenue and earnings than ARYA Sciences Acquisition Corp IV.
ARYA Sciences Acquisition Corp IV's return on equity of 0.00% beat Forian's return on equity.
In the previous week, Forian had 3 more articles in the media than ARYA Sciences Acquisition Corp IV. MarketBeat recorded 4 mentions for Forian and 1 mentions for ARYA Sciences Acquisition Corp IV. Forian's average media sentiment score of 0.00 beat ARYA Sciences Acquisition Corp IV's score of -0.22 indicating that ARYA Sciences Acquisition Corp IV is being referred to more favorably in the media.
ARYA Sciences Acquisition Corp IV has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500. Comparatively, Forian has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
Forian received 9 more outperform votes than ARYA Sciences Acquisition Corp IV when rated by MarketBeat users.
48.1% of ARYA Sciences Acquisition Corp IV shares are owned by institutional investors. Comparatively, 19.3% of Forian shares are owned by institutional investors. 53.5% of ARYA Sciences Acquisition Corp IV shares are owned by company insiders. Comparatively, 31.3% of Forian shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Forian has a consensus target price of $7.67, suggesting a potential upside of 188.22%. Given ARYA Sciences Acquisition Corp IV's higher probable upside, analysts clearly believe Forian is more favorable than ARYA Sciences Acquisition Corp IV.
Summary
Forian beats ARYA Sciences Acquisition Corp IV on 9 of the 12 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding FORA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
